Loading...

Alnylam Pharmaceuticals, Inc.

ALNYNASDAQ
Healthcare
Biotechnology
$443.64
$-10.74(-2.36%)

Alnylam Pharmaceuticals, Inc. (ALNY) Stock Overview

Explore Alnylam Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B+

Score: 74.7/100

Key Financials

Market Cap58.2B
P/E Ratio-180.84
EPS (TTM)$-2.45
ROE-2.74%
Fundamental Analysis

AI Price Forecasts

1 Week$318.21
1 Month$417.38
3 Months$346.97
1 Year Target$302.24

ALNY Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Alnylam Pharmaceuticals, Inc. (ALNY) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 87.06, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $302.24.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -180.84 and a market capitalization of 58.2B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-6.98%
5-Day Change
-12.00%
1-Month Change
-2.91%
3-Month Change
-4.92%
6-Month Change
-18.79%
Year-to-Date (YTD) Change
-3.14%
1-Year Change
48.47%
3-Year Change
43.73%
5-Year Change
90.14%
All-Time (Max) Change
3665.06%

Contact Information

617 551 8200
675 West Kendall Street, Cambridge, MA, 02142

Company Facts

2,230 Employees
IPO DateJun 1, 2004
CountryUS
Actively Trading

Frequently Asked Questions

;